Articles From: BioMarin Completes Additional Partial Exchange of Convertible Notes Due 2017 for Common Stock to BioMed Realty Trust Reports Fourth Quarter And Full-Year 2012 Financial Results


2013/3/25
SAN RAFAEL, Calif., March 25, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that an additional six holders of its 1.875% Convertible Senior Subordinated Notes due 2017 have agreed to exchange $75.8 million in aggregate principle amount of the notes for approximately 3.7 million shares of the Company's common stock.
Sign-up for BioMarin Completes Additional Partial Exchange of Convertible Notes Due 2017 for Common Stock investment picks
2013/3/18
SAN RAFAEL, Calif., March 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that seven holders of its 1.875% Convertible Senior Subordinated Notes due 2017 have agreed to exchange approximately $139.2 million in aggregate principal amount of the notes for approximately 6.8 million shares of the Company's common stock.
Sign-up for BioMarin Completes Partial Exchange of Convertible Notes Due 2017 for Common Stock investment picks
2013/2/20
SAN RAFAEL, Calif., Feb.
Sign-up for BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) investment picks
2013/3/19
NOVATO, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on March 15, 2013, the compensation committee of BioMarin's board of directors approved the grant to 20 employees of stock options to purchase 32,100 shares of common stock in the aggregate and the grant to 15 of the 20 employees of 4,615 restricted stock units in the aggregate.
Sign-up for BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) investment picks
2013/4/18
SAN RAFAEL, Calif., April 18, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that on April 15, 2013, the compensation committee of BioMarin's board of directors approved the grant to 27 employees of stock options to purchase 32,500 shares of common stock in the aggregate and the grant to 25 of the 27 employees of 8,280 restricted stock units in the aggregate.
Sign-up for BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) investment picks
2013/4/1
SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has submitted a Clinical Trial Application (CTA) with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for BMN-190, a recombinant human tripeptidyl peptidase 1 (rhTPP1) for the treatment of patients with neuronal ceroid lipofuscinosis type 2 (NCL-2), a form of Batten disease.
Sign-up for BioMarin Submits CTA for BMN-190 for Batten Disease investment picks
2013/4/1
SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Vimizim (BMN-110, elosulfase alfa), an enzyme replacement therapy under evaluation for the treatment of patients with the rare lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome.
Sign-up for BioMarin Submits Vimizim BLA to the U.S. FDA for the Treatment of MPS IVA investment picks
2013/4/24
SAN RAFAEL, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Vimizim (BMN-110, elosulfase alfa), an enzyme replacement therapy under evaluation for the treatment of patients with the rare lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), also called Morquio A Syndrome.
Sign-up for BioMarin Submits Vimizim MAA to EMA for the Treatment of MPS IVA investment picks
2013/3/19
BMN-701 Meaningfully Improves Respiratory Endpoints Phase 2/3 Switch Study Expected to Begin by December 2013 SAN RAFAEL, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today results from POM-001, the Phase 1/2 trial for BMN-701, a fusion protein of insulin-like growth factor 2 and acid alpha-glucosidase (IGF2-GAA) for the treatment of late-onset Pompe disease.
Sign-up for BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Development investment picks
2013/4/4
SAN RAFAEL, Calif., April 4, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 25, at 5:00 p.m. ET to discuss first quarter 2013 financial results.
Sign-up for BioMarin to Host First Quarter 2013 Financial Results Conference Call and Webcast on Thursday, April 25 at 5:00 p.m. ET investment picks
2013/5/2
SAN RAFAEL, Calif., May 2, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Maher, Senior Vice President of Product Development at BioMarin, will present a company update at the Baird Growth Stock Conference on Tuesday, May 7, 2013 at 9:45 a.m. CT.
Sign-up for BioMarin to Present at the Baird Growth Stock Conference investment picks
2013/2/6
SAN RAFAEL, Calif., Feb.
Sign-up for BioMarin to Present at the BIO CEO & Investor Conference investment picks
2013/5/14
SAN RAFAEL, Calif., May 14, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Chief Financial Officer at BioMarin, will present a company update at the UBS Global Healthcare Conference on Tuesday, May 21, 2013 at 9:00 a.m. ET.
Sign-up for BioMarin to Present at the UBS Global Healthcare Conference investment picks
2013/4/8
Over 82,000 Square Feet of New Leasing Signed at PRC in 2013 SAN DIEGO , April 8, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced today that Risk Management Solutions, Inc. ("RMS"), a leader in risk modeling for businesses, has leased an additional 31,500 square feet at its Pacific Research Center in Newark, California .
Sign-up for BioMed Realty Announces 31,500 Square Foot Lease Expansion With Risk Management Solutions At The Pacific Research Center investment picks
2013/4/18
SAN DIEGO , April 18, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced today that its 2012 Online Annual Report and other proxy materials are now available at http://www.biomedrealty.com/12AR .
Sign-up for BioMed Realty Introduces Its 2012 Online Annual Report investment picks
2013/4/4
SAN DIEGO , April 4, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced today that it will commence construction on two new buildings comprising approximately 297,000 square feet and a parking structure at The Landmark at Eastview in Tarrytown, New York , expanding the campus to approximately 1.4 million square feet.
Sign-up for BioMed Realty To Develop 297,000 Square Feet In New York Fully Leased To Regeneron Pharmaceuticals investment picks
2013/3/20
Concurrently Agrees to Terminate Lease with Elan Corporation and Acquire Foster City Campus from Life Technologies SAN DIEGO , March 20, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced today the signing of two new leases for 15 years with Life Technologies Corporation (NASDAQ: LIFE) at its Science Center at Oyster Point property in the heart of the South San Francisco, California life science submarket.
Sign-up for BioMed Realty To Lease 204,900 Square Feet To Life Technologies At The Science Center at Oyster Point In South San Francisco investment picks
2013/2/19
SAN DIEGO , Feb.
Sign-up for BioMed Realty Trust Announces Exercise Of Option To Purchase Additional Shares Of Common Stock investment picks
2013/4/2
SAN DIEGO , April 2, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the full exercise of the underwriters' option to purchase additional shares of common stock in connection with BioMed Realty's previously announced follow-on offering that priced on March 27, 2013 .
Sign-up for BioMed Realty Trust Announces Exercise Of Option To Purchase Additional Shares Of Common Stock investment picks
2013/2/12
SAN DIEGO, Calif.
Sign-up for BioMed Realty Trust Announces Public Offering Of 11,500,000 Shares Of Common Stock investment picks
2013/3/26
SAN DIEGO , March 26, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced it has commenced a public offering of 15,000,000 shares of its common stock pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission.
Sign-up for BioMed Realty Trust Announces Public Offering Of 15,000,000 Shares Of Common Stock investment picks
2013/3/18
SAN DIEGO , March 18, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its board of directors has declared a first quarter 2013 dividend of $0.235 per share of common stock, The dividend is equivalent to an annualized dividend of $0.94 per common share.
Sign-up for BioMed Realty Trust Declares First Quarter 2013 Common Stock Dividend investment picks
2013/2/13
SAN DIEGO , Feb.
Sign-up for BioMed Realty Trust Prices Public Offering Of 12,700,000 Shares Of Common Stock investment picks
2013/3/27
SAN DIEGO , March 27, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the pricing of its public offering of 15,000,000 shares of its common stock at $21.40 per share.
Sign-up for BioMed Realty Trust Prices Public Offering Of 15,000,000 Shares Of Common Stock investment picks
2013/5/1
First Quarter Leasing Volume of 583,700 Square Feet SAN DIEGO , May 1, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) , a real estate investment trust (REIT) that delivers optimal real estate solutions for the life science industry, today announced financial results for the first quarter ended March 31, 2013 .
Sign-up for BioMed Realty Trust Reports First Quarter 2013 Financial Results investment picks
2013/2/5
Fourth Quarter Leasing Volume of 624,900 Square Feet; Fourth Quarter FFO and AFFO per Share Up 20.0% and 17.9% Over 2011, Respectively SAN DIEGO , Feb.
Sign-up for BioMed Realty Trust Reports Fourth Quarter And Full-Year 2012 Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: BioMarin Completes Additional Partial Exchange of Convertible Notes Due 2017 for Common Stock to BioMed Realty Trust Reports Fourth Quarter And Full-Year 2012 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity